Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 4Phase 3 1Phase 1/2 1

Status

Withdrawn 1Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 4

Conditions

Melanoma 106Carcinoma, Non-Small-Cell Lung 34Carcinoma, Renal Cell 23Prostatic Neoplasms 17Neoplasms 15Brain Neoplasms 15Neoplasm Metastasis 14Lung Neoplasms 12Breast Neoplasms 11Uveal Melanoma 10Pancreatic Neoplasms 10Sarcoma 9Small Cell Lung Carcinoma 7Urinary Bladder Neoplasms 6Squamous Cell Carcinoma of Head and Neck 6Kidney Neoplasms 6Diabetes Mellitus, Insulin-Dependent, 12 6Carcinoma, Transitional Cell 6Carcinoma, Hepatocellular 6Skin Neoplasms 5Ovarian Neoplasms 5Histiocytoma, Malignant Fibrous 5Colorectal Neoplasms 5Uterine Cervical Neoplasms 4Triple Negative Breast Neoplasms 4Recurrence 4Neuroendocrine Tumors 4Mesothelioma 4Glioblastoma 4Colonic Neoplasms 4

Interventions

Fluorouracil 87Leucovorin 78Oxaliplatin 77Irinotecan 76Bevacizumab 50Cetuximab 42Capecitabine 42Panitumumab 17Folfox protocol 16Floxuridine 11Chemotherapy, Adjuvant 11regorafenib 10IFL protocol 10Nivolumab 9Drug Therapy 9trifluridine tipiracil drug combination 8Surgical Procedures, Operative 8Neoadjuvant Therapy 8sargramostim 7pembrolizumab 7XELOX 7Specimen Handling 7Biopsy 7Trastuzumab 6Radiotherapy 6Magnetic Resonance Spectroscopy 6HMPL-013 6tislelizumab 5encorafenib 5Trifluridine 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Colonic Neoplasms × Ipilimumab × Clear all
NCT03026140 2026-03-05

NICHE

The Netherlands Cancer Institute

Phase 2 Recruiting
353 enrolled
Gastrointestinal

Colonic Neoplasms

NCT03350126 2025-07-23

NIPICOL

GERCOR - Multidisciplinary Oncology Cooperative Group

Phase 2 Active not recruiting
57 enrolled
Gastrointestinal

Colonic Neoplasms, Microsatellite Instability

NCT03442569 2025-07-01

PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC

UNC Lineberger Comprehensive Cancer Center

Phase 2 Completed
56 enrolled 13 charts
Gastrointestinal

Colonic Neoplasms

NCT05456165 2024-12-31

Study of an Individualized Vaccine Targeting Neoantigens in Combination With Immune Checkpoint Blockade for Patients With Colon Cancer

Gritstone bio, Inc.

Phase 2 Withdrawn
Gastrointestinal

Colonic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡